| Autor: |
Crombie, J., Jun, M., Wang, T., Mutebi, A., Wang, A., Chibber, A., Kamalakar, R., Ukropec, J., Blaedel, J., Kalsekar, A. |
| Předmět: |
|
| Zdroj: |
Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p719-720, 2p |
| Abstrakt: |
Patients had a DLBCL diagnosis after 1/1/2010, with >=1 prior line of systemic antineoplastic therapy (including an anti-CD20 antibody), and treatment with any of these novel therapies. B Results: b A total of 175 R/R DLBCL patients were included (median age 63 y, 60.6% male, median of 2 prior therapies); 29.1% had an international prognostic index score >=3, 61.7% had stage III/IV disease, and 65.7% had primary refractory disease. Novel treatments for these patients include chimeric antigen receptor T-cell (CAR T) therapy, polatuzumab vedotin plus bendamustine and rituximab (pola-BR), tafasitamab plus lenalidomide (tafa-len), loncastuximab (lonca), and selinexor. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text